Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: Associations with changing practice patterns

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 9, 2011, Pages 2280-2288

  Akizawa, Tadao ^a   Kido, Ryo ^b,c   Fukagawa, Masafumi ^d   Onishi, Yoshihiro ^b   Yamaguchi, Takuhiro ^b,e   Hasegawa, Takeshi ^b,f   Fukuhara, Shunichi ^c   Kurokawa, Kiyoshi ^g  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Institute for Health Outcomes and Process Evaluation Research   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^g NATIONAL GRADUATE INSTITUTE FOR POLICY STUDIES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; FALECALCITRIOL; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG TARGETING; FEMALE; HEMODIALYSIS; HUMAN; JAPAN; JAPANESE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; SECONDARY HYPERPARATHYROIDISM;

AGED; CALCIUM; COHORT STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; PHYSICIAN'S PRACTICE PATTERNS; RENAL DIALYSIS;

EID: 80052593568     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11501210     Document Type: Article

References (33)

1. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70: 1358-1366, 2006
2. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM: PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney 47: 149-156, 2006
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
4. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006
5. Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Fukuhara S, Akizawa T, Saito A, Asano Y, Kurokawa K, Pisoni RL, Port FK: Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: The Japan dialysis outcomes and practice patterns study. Hemodial Int 11: 340-348, 2007
6. Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M, Tominaga Y, Iseki K, Tsubakihara Y: Patient Registration Committee of the Japanese Society for Dialysis Therapy, Tokyo, Japan: Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 12: 49-54, 2008
7. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519-530, 2008
8. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
9. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[4 Suppl 3]: S1-S201, 2003
10. Wetmore JB, Quarles LD: Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clinc Pract Nephrol 5: 24-33, 2009
11. Indridason OS, Quarles LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 57: 282-292, 2000
12. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF: Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann Intern Med 147: 840-853, 2007
13. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004
14. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, Mc-Cary LC, Olson KA, Turner SA, Martin KJ: Achieving NKF-K/ DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67: 760-771, 2005
15. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14: 3270-3277, 2003
16. Guideline Working Group, Japanese Society for Dialysis Therapy: Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12: 514-525, 2008
17. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 76: S1-S130, 2009
18. Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C: Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results. Clin J Am Soc Nephrol 3: 1718-1725, 2008
19. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and design overview. Clin J Am Soc Nephrol 2: 898-905, 2007
20. Cannata-Andia JB, Fernandez-Martin JL, Zoccali C, London GM, Locatelli F, Ketteler M, Ferreira A, Covic A, Floege J, Gorriz JL, Rutkowski B, Memmos DE, Verbeelen D, Tielemans C, Teplan V, Bos WJ, Nagy J, Kramar R, Goldsmith DJ, Martin PY, Wuthrich RP, Pavlovic D, Benedik M: Current management of secondary hyperparathyroidism: A multicenter observational study (COSMOS). J Nephrol 21: 290-298, 2008
21. Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, Liu J, St Peter WL: Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 78: 578-589, 2010
22. Fukuhara S, Akizawa T, Fukagawa M, Onishi Y, Yamaguchi T, Hasegawa T, Kurokawa K: Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients (MBD-5D): Rationale and study design. Ther Apher Dial 15: 169-175, 2011
23. Fukagawa M, Komaba H, Onishi Y, Fukuhara S, Akizawa T: Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: Baseline data from the MBD-5D. Am J Nephrol 33: 427-437, 2011
24. Payne RB, Little AJ, Williams RB, Milner JR: Interpretation of serum calcium in patients with abnormal serum proteins. BMJ 4: 643-646, 1973
25. Spiegelman D, Hertzmark E: Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 162: 199-200, 2005
26. Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, Itami N, Ogata S, Kimata N, Shinoda T, Syouji T, Suzuki K, Taniguchi M, Tsuchida K, Nakamoto H, Nishi S, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Fujii N, Marubayashi S, Morita O, Wakai K, Wada A, Iseki K, Tsubakihara Y: An overview of dialysis treatment in Japan (as of Dec. 31, 2007). Ther Apher Dial 13: 457-504, 2009
27. Rothman KJ, Greenland S, Lash TL: Validity in Epidemiologic Studies In: Modern Epidemiology, 3rd ed., edited by Rothman KJ, Greenland S, Lash TL: Philadelphia, Lippincott Williams & Wilkins, 2008, pp 146-147
28. Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S: Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23: 328-335, 2008
29. Komaba H, Fukagawa M: KRN1493 Study Group: Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: A posthoc analysis of the KRN1493 study. Ther Apher Dial [Suppl 1]: S44-S49, 2008
30. St Peter WL, Li Q, Liu J, Persky M, Nieman K, Arko C, Block GA: Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 4: 354-360, 2009
31. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
32. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ: Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 3: 1423-1429, 2008
33. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT: Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group: The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: Association with mortality in dialysis patients. Am J Kidney Dis 46: 925-932, 2005